We project a 15% year-over-year increase in Tadalafil sales within the next three years, driven by expanding our direct-to-consumer marketing campaigns and strategic partnerships with leading telehealth providers. This growth will be supported by investment in clinical research to explore new formulations and delivery methods.
Expanding Market Reach
We will aggressively pursue new international markets, focusing initially on regions with high unmet medical needs and favorable regulatory environments. This includes securing necessary approvals in at least three new countries by 2026.
Product Diversification
We plan to launch two new related products within the next five years, leveraging our existing expertise and infrastructure. These will include a once-daily Tadalafil formulation and a novel combination therapy to address erectile dysfunction and associated conditions.
Technological Advancement
We will invest in advanced manufacturing technologies to improve production efficiency and reduce costs by 10% within the next two years. We’ll also incorporate AI-driven data analytics to enhance our understanding of consumer preferences and optimize our marketing strategies.
Strengthening Brand Positioning
We will build stronger brand awareness by partnering with trusted health organizations and sponsoring relevant medical conferences. This will involve a 20% increase in our marketing budget allocated to these activities.
